A new HPLC-UV method has been developed to measure the atypical antipsychotic quetiapine and different forms of fluvoxamine simultaneously, using a specific column and mobile phase.
The method involves a solid-phase extraction process that requires only 300 µL of plasma and uses citalopram as an internal standard, allowing for efficient analysis.
Validation results showed high extraction yields (over 93%), great precision (less than 4% RSD), and successful application to human plasma samples, achieving mean recovery rates exceeding 94%.